4. Allogeneic patients if: i. Patients had engrafted donor cells (i.e., > 20% donor T-cell from PB/PCR); and, ii. Patients NOT in CR after their allogeneic transplant, and off tacrolimus and/or mycophenolate mofetil for at least 3 to 4 weeks with no signs of GVHD; or, iii. Patients had evidence of relapse after their transplant who are off tacrolimus and/or mycophenolate mofetil or other immunosuppressants for GVHD for 3 to 4 weeks with no signs of GVHD (Prednisone doses </= 10 mg are permitted as stated previously).